7月2日 - ** 临床阶段生物技术公司 Dianthus Therapeutics DNTH.O 股价上涨 ~4.6% 至 18.78 美元
** 威廉-布莱尔（William Blair）启动了对DNTH的覆盖 ，评级为 "跑赢大盘"。
** 券商称，DNTH 的管理团队拥有丰富的经验，整个团队非常适合在竞争激烈的自身免疫性神经肌肉疾病市场上实施临床开发和商业化。
** William Blair 补充说，首席执行官 Marino Garcia 的专业知识将使 Dianthus 在未来几年内从一家处于中期阶段的临床开发公司过渡到处于后期阶段的商业实体时处于有利地位。
** 12家券商均给予该股 "买入 "或更高的评级；其PT中值为50美元--LSEG数据
** 包括本交易日的走势在内，该股今年累计下跌约14.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.